Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Accumulated Expenses (2024 - 2025)

Allarity Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 49.03% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, down 49.03%, while the annual FY2025 figure was $2.7 million, 49.03% down from the prior year.
  • Accumulated Expenses reached $2.7 million in Q4 2025 per ALLR's latest filing, down from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.3 million in Q1 2025 to a low of $192000.0 in Q2 2024.